Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
暂无分享,去创建一个
M. Piccart | M. Nooij | R. Paridaens | J. Bogaerts | P. Therasse | D. Cameron | L. Dirix | L. Beex | T. Čufer
[1] S. Verma,et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer , 2008, Cancer.
[2] P. Lønning,et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.
[3] R. Paridaens,et al. First mature analysis of the Intergroup Exemestane Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Siegfried. Hormone replacement therapy and decreased lung cancer survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[6] D. Timmerman,et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Dixon. Exemestane and aromatase inhibitors in the management of advanced breast cancer , 2004, Expert opinion on pharmacotherapy.
[8] M. Dowsett. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .
[9] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[10] M. Piccart,et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] C. Boni,et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[13] C. Boni,et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Lønning,et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Dirix,et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Fehrenbacher,et al. Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer , 1999 .
[19] M. Piccart,et al. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] C. Vogel,et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Paridaens,et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. , 1998, Anti-cancer drugs.
[22] R. Paridaens,et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. , 1997, European journal of cancer.
[23] G. Hortobagyi,et al. Use of tamoxifen for breast cancer: twenty-eight years later. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[25] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.